BACKGROUND: We examined adherence to highly active antiretroviral therapy (HAART) in the homeless population, a population thought to be at high risk for poor adherence to therapy and for development of drug-resistant strains of human immunodeficiency virus (HIV). METHODS: We performed a 12-month prospective study of 148 persons receiving HAART who were identified in a stratified screening of the homeless and marginally housed. We sampled in lunch lines, shelters, and hotels in 3 neighborhoods of San Francisco, California. We used pill counts at unannounced home visits as the primary measure of adherence. RESULTS: Of 148 individuals sampled, 46 (31%) discontinued HAART during the study. Average adherence in the group of those who discontinued HAART was 51%, and 9% of these subjects had undetectable virus loads (i.e., <400 copies/mL) at the last follow-up visit. Predictors of discontinuation of therapy were depressive symptoms, injection drug use, African American ethnicity, and early poor adherence. Of 148 subjects, 102 (69%) continued to receive HAART throughout the study period. Average adherence in the group of those who continued to receive HAART was 74%, and 55% of these subjects had undetectable virus loads at the last follow-up visit. Predictors of lower average adherence in this group were African American ethnicity and use of crack cocaine; men who had sex with men had higher adherence. CONCLUSIONS: One-third of homeless and marginally housed persons receiving HAART discontinued therapy during the follow-up period and would benefit from adherence interventions directed at sustaining therapy; two-thirds continued to receive therapy at adherence levels comparable to those found with other clinical populations.
BACKGROUND: We examined adherence to highly active antiretroviral therapy (HAART) in the homeless population, a population thought to be at high risk for poor adherence to therapy and for development of drug-resistant strains of human immunodeficiency virus (HIV). METHODS: We performed a 12-month prospective study of 148 persons receiving HAART who were identified in a stratified screening of the homeless and marginally housed. We sampled in lunch lines, shelters, and hotels in 3 neighborhoods of San Francisco, California. We used pill counts at unannounced home visits as the primary measure of adherence. RESULTS: Of 148 individuals sampled, 46 (31%) discontinued HAART during the study. Average adherence in the group of those who discontinued HAART was 51%, and 9% of these subjects had undetectable virus loads (i.e., <400 copies/mL) at the last follow-up visit. Predictors of discontinuation of therapy were depressive symptoms, injection drug use, African American ethnicity, and early poor adherence. Of 148 subjects, 102 (69%) continued to receive HAART throughout the study period. Average adherence in the group of those who continued to receive HAART was 74%, and 55% of these subjects had undetectable virus loads at the last follow-up visit. Predictors of lower average adherence in this group were African American ethnicity and use of crack cocaine; men who had sex with men had higher adherence. CONCLUSIONS: One-third of homeless and marginally housed persons receiving HAART discontinued therapy during the follow-up period and would benefit from adherence interventions directed at sustaining therapy; two-thirds continued to receive therapy at adherence levels comparable to those found with other clinical populations.
Authors: M-J Milloy; Thomas Kerr; David R Bangsberg; Jane Buxton; Surita Parashar; Silvia Guillemi; Julio Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2011-11-22 Impact factor: 5.078
Authors: Mohamed Elrefaei; Candace M Burke; Chris A R Baker; Norman G Jones; Stephanie Bousheri; David R Bangsberg; Huyen Cao Journal: AIDS Res Hum Retroviruses Date: 2010-03 Impact factor: 2.205
Authors: Neel K Gupta; Amber Nolan; Antonio Omuro; Erin G Reid; Chia-Ching Wang; Gabriel Mannis; Michael Jaglal; Julio C Chavez; Paul G Rubinstein; Ann Griffin; Donald I Abrams; Jimmy Hwang; Lawrence D Kaplan; Judith A Luce; Paul Volberding; Patrick A Treseler; James L Rubenstein Journal: Neuro Oncol Date: 2016-08-30 Impact factor: 12.300
Authors: Sheri D Weiser; Edward A Frongillo; Kathleen Ragland; Robert S Hogg; Elise D Riley; David R Bangsberg Journal: J Gen Intern Med Date: 2008-10-25 Impact factor: 5.128